07 Jan 2016
Update on simtuzumab by Gilead
The news that Gilead had stopped its Phase II trial of simtuzumab (an antibody developed using Abzena’s Composite Human AntibodyTM technology) in lung fibrosis was slightly disappointing, but encouragingly Phase II trials continue in both liver fibrosis and PSC. We continue to expect significant newsflow from Abzena’s portfolio of licensed Abzena inside programmes over the coming year, including Phase II start for GS-5745 (by Gilead) in Rheumatoid Arthritis, potential Phase II data on simtuzumab ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Update on simtuzumab by Gilead
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
07 Jan 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
The news that Gilead had stopped its Phase II trial of simtuzumab (an antibody developed using Abzena’s Composite Human AntibodyTM technology) in lung fibrosis was slightly disappointing, but encouragingly Phase II trials continue in both liver fibrosis and PSC. We continue to expect significant newsflow from Abzena’s portfolio of licensed Abzena inside programmes over the coming year, including Phase II start for GS-5745 (by Gilead) in Rheumatoid Arthritis, potential Phase II data on simtuzumab ....